Evidence map›Paper›PMID 35011438›Full record

ArticleMolecules (Basel, Switzerland)2021

Terpenoid Hydrazones as Biomembrane Penetration Enhancers: FT-IR Spectroscopy and Fluorescence Probe Studies.

Mariia Nesterkina, Serhii Smola, Nataliya Rusakova, Iryna Kravchenko

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. 30th Annual GPPharmaceuticals (Basel, Switzerland) · 2023
    Article
  2. Women in Bioorganic Chemistry.Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mariia NesterkinaDepartment of Organic and Pharmaceutical Technologies, Odessa National Polytechnic University, 65044 Odessa, Ukraine.ORCID 0000-0002-3201-7961
Serhii SmolaA.V. Bogatsky Physico-Chemical Institute, National Academy of Sciences of Ukraine, 65080 Odessa, Ukraine.
Nataliya RusakovaA.V. Bogatsky Physico-Chemical Institute, National Academy of Sciences of Ukraine, 65080 Odessa, Ukraine.
Iryna KravchenkoDepartment of Organic and Pharmaceutical Technologies, Odessa National Polytechnic University, 65044 Odessa, Ukraine.
National Academy of Sciences of Ukraine · UAOdessa National Polytechnic University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrazones based on mono- and bicyclic terpenoids (verbenone, menthone and carvone) have been investigated in vitro as potential biomembrane penetration enhancers. In this regard, liposomes composed of lecithin or cardiolipin as phospholipid phase components with incorporated fluorescence probes have been prepared using the thin-film ultrasonic dispersion method. The mean particle size of the obtained liposomes, established using laser diffraction, was found to be 583 ± 0.95 nm, allowing us to categorize them as multilamellar vesicles (MLVs) according to their morphology. Pursuant to fluorescence analysis, we may assume a reduction in microviscosity and, consequently, a decrease in the packing density of lecithin and cardiolipin lipids to be the major mechanism of action for terpenoid hydrazones

Indexed as

Spectroscopy, Fourier Transform InfraredFluorescenceFluorescent DyesHydrazonesHydrogen BondingLipidsLiposomesMolecular StructurePhospholipidsTerpenesFluorescent DyesHydrazonesLipidsLiposomesPhospholipidsTerpenesfluorescence probeFT-IR spectroscopyhydrazoneslaser diffractionlipidsliposomespenetration enhancerspyrenestratum corneumterpenes

Identifiers

PMID35011438
PMCPMC8746376
OpenAlexW4200326270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.